Haleon plc (NYSE:HLN) Holdings Raised by Ritholtz Wealth Management

Ritholtz Wealth Management increased its position in shares of Haleon plc (NYSE:HLN) by 128.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,214 shares of the company’s stock after purchasing an additional 33,249 shares during the quarter. Ritholtz Wealth Management’s holdings in Haleon were worth $565,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. AE Wealth Management LLC increased its holdings in shares of Haleon by 6.1% in the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock worth $159,000 after acquiring an additional 1,098 shares during the period. Lake Street Advisors Group LLC increased its stake in shares of Haleon by 5.4% in the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock valued at $237,000 after purchasing an additional 1,143 shares during the period. Synovus Financial Corp raised its holdings in shares of Haleon by 0.8% during the third quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock valued at $1,575,000 after buying an additional 1,216 shares during the last quarter. Hexagon Capital Partners LLC boosted its position in shares of Haleon by 18.5% during the third quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company’s stock worth $84,000 after buying an additional 1,238 shares during the period. Finally, Peapack Gladstone Financial Corp grew its holdings in Haleon by 3.2% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock worth $474,000 after buying an additional 1,390 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Up 0.5 %

Shares of NYSE:HLN opened at $9.24 on Tuesday. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The firm has a fifty day moving average price of $9.54 and a 200 day moving average price of $9.72. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $41.80 billion, a PE ratio of 27.16, a P/E/G ratio of 2.52 and a beta of 0.29.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.